Brachytherapy (BT), using either a low-dose-rate (LDR) or mostly high-dose-rate (HDR) technique, is the device able to deliver the highest dose-rate in the most conformal way It is used as monotherapy or in combination with external beam radiotherapy (EBRT). LDR-BT is mostly used as monotherapy; HDR-BT is combined with EBRT +/– adjuvant hormone therapy In patients with low-risk disease and in selected intermediate-risk patients, LDR-BT ensures long-term good disease control rates and HDR-BT shows similar results, even if with shorter follow-up. In patients with intermediate/high risk disease the combination therapy (EBRT + HDR-BT) provides better oncological outcomes compared to EBRT monotherapy, even if the role of adjuvant hormone therapy is still unclear. Literature shows variable efficacy of BT in case of local recurrence after EBRT and radical prostatectomy even if few cases have been reported with short follow-up. Side effects are acceptable (urogenital toxicity, urinary incontinence, sexual function) and comparable with the other treatment modalities. So far, randomized controlled trials comparing the different treatment modalities are necessary to clarify indications and real efficacy.
LandisS.H., MurrayT., BoldenS.Cancer statistics, 1999. CA Cancer J Clin1999; 49: 8–31.
2.
CatalonaW.J., SmithD.S., RatliffT.L., BaslerJ.W.Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA1993; 270: 948–954.
3.
AlbertsenP.C., HanleyJ.A., BarrowsG.H.Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst2005; 97: 1248–1253.
WolfA.M., WenderR.C., EtzioniR.B.American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin2010; 60: 70–98.
7.
ThompsonI.M., PaulerD.K., GoodmanP.J.Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med2004; 350: 2239–2246. Erratum, N Engl J Med 2004; 351: 1470.
WiltT.J., MacDonaldR., RutksI., ShamliyanT.A., TaylorB.C., KaneR.L.Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med2008; 148: 435–448.
10.
AhmedH.U., FreemanA., KirkhamA.Focal therapy for localized prostate cancer: A phase I/II trial. J Urol185: 1246–1254.
11.
CooperbergM.R., BroeringJ.M., CarrollP.R.Time trends and local variation in primary treatment of localized prostate cancer, J Clin Oncol2010; 28: 1117–1123.
12.
KlotzL., ZhangL., LamA.Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer, J Clin Oncol2008; 28: 126–131.
13.
TsengK.S., LandisP., EpsteinJ.I.Risk stratification of men choosing surveillance for low risk prostate cancer. J Urol2010; 183: 1779–1785.
14.
SciarraA., BarentszJ., BjartellA.Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. Eur Urol2011; 59(6): 962–977.
15.
ZelefskyM.J., FuksZ., HuntM.High dose radiation delivered by intensity-modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol2001; 166: 876–881.
16.
ZelefskyM.J., YamadaY., FuksZ.Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys2008; 71: 1028–1033.
17.
PollackA., ZagarsG.K., StarkschallG.Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys2002; 53: 1097–1105.
18.
ChanL.W., XiaP., GottschalkA.R.Proposed rectal dose constraints for patients undergoing definitive whole pelvic radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys2008; 72: 69–77.
19.
MichalskiJ.M., GayH., JacksonA., TuckerS.L., DeasyJ.O.Radiation dose volume effects in radiation-induced rectal injury. Int J Radiat Oncol Biol Phys2010; 76: S123–129.
20.
TuckerS.L., DongL., BoschW.R.Late rectal toxicity on RTOG 94–06: analysis using a mixture lyman model. Int J Radiat Oncol Biol Phys2010; 78: 1253–1260.
21.
SharmaN.K., LiT., ChenD.Y., PollackA., HorwitzE.M., BuyyounouskiM.K.Intensity-modulated radiotherapy reduces gastrointestinal toxicity in patients treated with androgen deprivation therapy for prostate cancer. Int J Radiat Oncol Biol Phys2011; 80(2): 437–444.
22.
WhitmoreW.F.Jr., HilarisB., GrabstaldH.Retropubic implantation to iodine 125 in the treatment of prostatic cancer. J Urol1972; 108: 918–920.
23.
RagdeH., BlaskoJ.C., GrimmP.D.Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma. Cancer1997; 80: 442–453.
24.
KovacsG., PotterR., TillmannL.GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping-sources for localized prostate cancer. Radiother Oncol2005; 74: 137–148.
National Comprehensive Cancer Network Guide Lines 2013. www.nccn.org/professionals/physician_gls/. MerrickG.S., ButlerW.M., GalbreathR.W.Biochemical outcomefor hormone-naive patients with Gleason score 3+4 versus 4+3 prostate cancer undergoing permanent prostatebrachytherapy. Urology2002; 60: 98–103.
28.
WallnerK., LeeH., WassermanS.Low risk of urinaryin-continence following prostate brachytherapy in patientswith a prior transurethral prostate resection. Int J Radiat Oncol Biol Phys1997; 37: 565–569.
29.
LeeW.R.The role of androgen deprivation therapy combinedwith prostate brachytherapy. Urology2002; 60(3 Suppl. 1): 39–44.
30.
WhitmoreW.F.Jr., HilarisB., GrabstaldH.Retropubic implantation to iodine 125 in the treatment of prostatic cancer. J Urol1972; 108: 918–920.
31.
PeschelR.E., ColbergJ.W., ChenZ., NathR., WilsonL.D.Iodine 125 versus palladium103 implants for prostate cancer: clinical outcomes and complications. Cancer J2004; 10: 170–174.
32.
WallnerK., MerrickG., TrueL., SutliefS., CavanaghW., ButlerW.125I versus 103Pd for low-risk prostate cancer: preliminary PSA outcomes from a prospective randomized multicenter trial. Int J Radiat Oncol Biol Phys2003; 57: 1297–1303.
33.
SmithR.P., JonesH.A., BeriwalS., GokhaleA., BenoitR.Predictors of urinary morbidityin cs-131 prostate brachytherapy implants. Int J Radiat Oncol Biol Phys2011; 81(3): 745–750.
34.
TomaszewskiJ.J., SmaldoneM.C., MakarounS., SmithR.P., BeriwalS., BenoitR.M.Cesium 131 versus iodine 125 implants for prostate cancer: evaluation of early PSA response. Can J Urol2010; 17: 5360–5364.
RosenthalS.A., BittnerN.H., BeyerD.C.American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR)practice guideline for the transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys2011; 79: 335–341.
37.
CrookJ.M., Gomez-IturriagaA., WallaceK.Comparison of health-related quality of life 5 years after SPIRIT: Surgical Prostatectomy Versus Interstitial Radiation Intervention Trial. J Clin Oncol2011; 29(4): 362–368.
38.
WiltT.J., MacDonaldR., RutksI., ShamliyanT.A., TaylorB.C., KaneR.L.Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med2008; 148: 435–448.
39.
KoukourakisG., KelekisN., ArmonisV., KoulouliasV.Brachytherapy for prostate cancer: a systematic review. Adv Urol2009: 327945.
40.
CrookJ., BorgJ., EvansA.10-year experience with I-125 prostate brachytherapy at the Princess Margaret Hospital: results for 1,100 patients. Int J Radiat Oncol Biol Phys2011; 80(5): 1323–1329.
41.
StockR.G., KleinT.J., CesarettiJ.A., StoneN.N.Prognostic significance of 5-year PSA value for predicting prostate cancer recurrence after brachytherapy alone and combined with hormonal therapy and/or external beam radiotherapy. Int J Radiat Oncol Biol Phys2009; 74: 753–758.
42.
GrimmP.D., BlaskoJ.C., SylvesterJ.E., MeierR.M., CavanaghW.10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys2001; 51: 31–40.
43.
StoneN.N., StockR.G., CesarettiJ.A., UngerP.Local control following permanent prostate brachytherapy: effect of high biologically effective dose on biopsy results and oncologic outcomes. Int J Radiat Oncol Biol Phys2010; 76: 355–360.
44.
MorrisW.J., KeyesM., PalmaD.Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer. Urology2009; 73: 860–865.
45.
MartinezA., GalalaeR., GonzalezJ., MitchellC., GustafsonG., KovacsG.No apparent benefit at 5 years from a course of neoadjuvant/concurrent androgen deprivation for patients with prostate cancer treated with a high total radiation dose. J Urol2003; 170: 2296–2301.
46.
KraussD., KestinL., YeH.Lack of benefit for the addition of androgen deprivation therapy to dose-escalated radiotherapy in the treatment of intermediate- and high-risk prostate cancer. Int J Radiat Oncol Biol Phys2011; 80(4): 1064–1071.
47.
PeinemannF., GrouvenU., BartelC.Permanent interstitial Low-Dose-Rate Brachytherapy for Patients with Localised Prostate Cancer: A systematic Review of randomised and Nonrandomised Controlled Clinical Trials. Eur Urol2011; 60: 881–893.
48.
ZhouE.H., EllisR.J., CherulloE.Radiotherapy and survival in prostate cancer patients: a population-based study. Int J Radiat Oncol Biol Phys2009; 73: 15–23.
PinkawaM., PirothM.D., HolyR.Prostate-specific antigen kinetics following external-beam radiotherapy and temporary (Ir-192) or permanent (I-125) brachytherapy for prostate cancer. Radiother Oncol2010; 96: 25–29.
51.
PicklesT., KeyesM., MorrisW.J.Brachytherapy or conformal external radiotherapy for prostate cancer: a single-institution matched-pair analysis. Int J Radiat Oncol Biol Phys2010; 76: 43–49.
52.
WongW.W., VoraS.A., SchildS.E.Radiation dose escalation for localized prostate cancer: intensity-modulated radiotherapy versus permanent transperineal brachytherapy. Cancer2009; 115: 5596–5606.
53.
RoachM.III, HanksG., ThamesH.JrDefining biochemicalfailure following radiotherapy with or without hormonal therapy inmen with clinically localized prostate cancer: recommendations ofthe RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys2006; 65: 965–974.
54.
ThompsonA., KeyesM., PicklesT.Evaluating the Phoenixdefinition of biochemical failure after 125I prostate brachytherapy: can PSA kinetics distinguish PSA failures from PSA bounces?Int J Radiat Oncol Biol Phys2010; 78: 415–421.
55.
MedizinischerDienst des Spitzenverbandes Bund der Krankenkassen, Kompetenz Centrum Onkologie, Institutfü r Qualitä t undWirtschaftlichkeitimGesundheitswesen, GKV-Spitzenverband.PräferenzbasierteStudiezur Evaluation der interstitiellenBrachytherapiebeimlokalbegrenztenProstata-karzinommitniedrigemRisiko; Studienkonzeption. G-BA GemeinsamerBundesausschussWeb site. http://www.g-ba.de/downloads/40-268-1103/2009-12-17-RMvV-Brachy_TrG.pdf. Updated 2009 (24.09.201009.11.2010).
56.
ParulekarW.A phase III study of active surveillance therapy againstradical treatment in patients diagnosed with favourable risk prostatecancer (START) [identifier NCT00499174]. ClinicalTrials.govWeb site. http://clinicaltrials.gov/ct2/show/NCT00499174.
57.
BottomleyD.SABRE 1: Surgery Against Brachytherapy; a Randomised Evaluation. Randomised controlled trial of brachytherapyversus radical prostatectomy in good risk prostate cancer: a feasibility study. ISRCTN Register Web site. http://www.controlledtrials.com/ISRCTN88144169.
58.
ShahC., LanniT.B.J., GhilezanM.I.Brachytherapy provides comparable outcomes and improved cost-effectiveness in the treatment of low/intermediate prostate cancer. Brachytherapy2012; 11: 441–445.
59.
PradaP.J., JimenezI., Gonzalez-SuarezH.High-dose-rate interstitial brachytherapy as monotherapy in one fraction and transperineal hyaluronic acid injection into the perirectal fat for the treatment of favorable stage prostate cancer: treatment description and preliminary results. Brachytherapy2012; 11: 105–110.
60.
RogersC.L., AlderS.C., RogersR.L.High dose brachytherapy as monotherapy for intermediate risk prostate cancer. J Urol2012; 187: 109–116.
61.
ZamboglouN., TselisN., BaltasD.High-dose-rate interstitial brachytherapy as monotherapy for clinically localized prostate cancer: treatment evolution and mature results. Int J Radiat Oncol Biol Phys2013; 85: 672–678.
62.
BarkatiM., WilliamsS.G., ForoudiF.High-doserate brachytherapy as a monotherapy for favorable-risk prostate cancer: a phase II trial. Int J Radiat Oncol Biol Phys2012; 82: 1889–1896.
63.
YoshiokaY., KonishiK., SumidaI.Monotherapeutic high dose- rate brachytherapy for prostate cancer: five-year results of an extreme hypofractionation regimen with 54 Gy in nine fractions. Int J Radiat Oncol Biol Phys2011; 80: 469–475.
64.
DemanesD.J., MartinezA.A., GhilezanM.High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys2011; 81: 1286–1292.
65.
HoskinP., RojasA., LoweG.High-dose-rate brachytherapy alone for localized prostate cancer in patients at moderate or high risk of biochemical recurrence. Int J Radiat Oncol Biol Phys2012; 82: 1376–1384.
66.
GhilezanM., MartinezA., GustasonG.High-dose-rate brachytherapy as monotherapy delivered in two fractions within one day for favorable/intermediate-risk prostate cancer: preliminary toxicity data. Int J Radiat Oncol Biol Phys2012; 83: 927–932.
67.
DeutschI., ZelefskyM.J., ZhangZ.Comparison of PSA relapse-free survival in patients treated with ultra-high-dose IMRT versus combination HDR brachytherapy and IMRT. Brachytherapy2010; 9: 313–318.
68.
StoneN.N., StoneM.M., RosensteinB.S., UngerP., StockR.G.Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy. J Urol2011; 185: 495–500.
69.
LawtonC.A., YanY., LeeW.R.Long-term results of an RTOGphase II trial (00–19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys2012; 82: 795–801.
70.
MerrickG.S., ButlerW.M., WallnerK.E.Impact of supplemental external beam radiotherapy and/or androgen deprivationtherapy on biochemical outcome after permanent prostatebrachytherapy. Int J Radiat Oncol Biol Phys2005; 61: 32–43.
71.
CritzF.A., LevinsonK.10-Year disease-free survival rates after simultaneous irradiation for prostate cancer with a focus oncalculation methodology. J Urol2004; 172: 2232–2238.
72.
TairaA.V., MerrickG.S., ButlerW.M.Long-term outcome for clinically localized prostate cancer treated with permanentinterstitial brachytherapy. Int J Radiat Oncol Biol Phys2011; 79: 1336–1342.
73.
MerrickG.S., WallnerK.E., ButlerW.M.20 Gy versus 44 Gy of supplemental external beam radiotherapy with palladium-103 for patients with greater risk disease: results of a prospective randomized trial. Int J Radiat Oncol Biol Phys2012; 82: 449–455.
74.
ShilkrutM., MerrickG.S., McLaughlinP.W.The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer. Cancer2013; 119: 681–690.
75.
KhorR., DuchesneG., TaiK.H.Direct 2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs external beam radiation therapy alone for prostate cancer. Int J Radiat Oncol Biol Phys2013; 85: 679–685.
76.
CuryF.L., DuclosM., AprikianA.Single-fraction high dose-rate brachytherapy and hypofractionated external-beam radiation therapy in the treatment of intermediate-risk prostate cancer e long term results. Int J Radiat Oncol Biol Phys2012; 82: 1417–1423.
77.
PradaP.J., GonzalezH., FernandezJ.Biochemical outcomeafter high-dose-rate intensity modulated brachytherapy with external beam radiotherapy: 12 years of experience. BJU Int2012; 109: 1787–1793.
78.
KotechaR., YamadaY., PeiX.Clinical outcomes of high dose-rate brachytherapy and external beam radiotherapy in the management of clinically localized prostate cancer. Brachytherapy2013; 12: 44–49.
79.
KaprealianT., WeinbergV., SpeightJ.High-dose-rate-brachytherapy boost for prostate cancer: comparison of two different fractionation schemes. Int J Radiat Oncol Biol Phys2012; 82: 222–227.
80.
WhalleyD., PatanjaliN., JacksonM.HDR brachytherapy combined with external beam radiation for localised prostate cancer: early experience from the Sydney Cancer Centre. J Med Imaging Radiat Oncol2012; 56: 220–226.
81.
GhadjarP., KellerT., RentschC.A.Toxicity and early treatment outcomes in low- and intermediate-risk prostate cancer managed by high-dose-rate brachytherapy as a monotherapy. Brachytherapy2009; 8: 45–51.
82.
ZwahlenD.R., AndrianopoulosN., MathesonB., DuchesneG.M., MillarJ.L.High-dose-rate brachytherapy in combination with conformal external beam radiotherapy in the treatment of prostate cancer. Brachytherapy2010; 9: 27–35.
83.
PellizzonA.C., FogaroliR.C., SilvaM.L.High-dose-rate brachytherapy combined with hypofractionated external beam radiotherapy for men with intermediate or high risk prostate cancer: analysis of short- and medium-term urinary toxicity and biochemical control. Int J Clin Exp Med2011; 4: 43–52.
84.
PietersB.R., de BackD.Z., KoningC.C., ZwindermanA.H.Comparison of three radiotherapy modalities on biochemical control and overall survival for the treatment of prostate cancer: a systematic review. Radiother Oncol2009; 93: 168–173.
85.
VargasC., MartínezA., GalalaeR.High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features. Prostate Cancer Prostatic Dis2006; 9: 245–253.
86.
MartinezA.A., DemanesD.J., GalalaeR.Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime. Int J Radiat Oncol Biol Phys2005; 62: 1322–1331.
87.
HurwitzM.D., HalabiS., ArcherL.Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate risk prostate cancer: long term results of CALGB 99809. Cancer2011; 117: 5579–5588.
88.
KonakaH., EgawaS., SaitoS.Tri-modality therapy with I-125 brachitherapy, external beam radiation therapy for high- localized prostate cancer (TRIP): study protocol for a phase III, multicenter, randomized controlled trial. BMC Cancer2012; 12: 110.
89.
KeyesM., MillerS., MoravanV.Acute and late urinary toxicity in 606 prostate brachytherapy patients. Radiother Oncol2006; 80: S41–A141.
90.
KeyesM., MillerS., MoravanV., PicklesT.Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients. Int J Radiat Oncol Biol Phys2009; 73: 1023–1032.
91.
MortonG.C., LoblawD.A., SankreachaR.Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life. Int J Radiat Oncol Biol Phys2010; 77: 811–817.
92.
MartensC., PondG., WebsterD., McLeanM., GillanC., CrookJ.Relationship of the international prostate symptom score with urinary flow studies, and catheterization rates following 125I prostate brachytherapy. Brachytherapy2006; 5: 9–13.
93.
CrookJ., McLeanM., CattonC., YeungI., TsihliasJ., PintilieM.Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation. Int J Radiat Oncol Biol Phys2002; 52: 453–460.
94.
LockeJ., EllisW., WallnerK., CavanaghW., BlaskoJ.Risk factors for acute urinary retention requiring temporary intermittent catheterization after prostate brachytherapy: A prospective study. Int J Radiat Oncol Biol Phys2002; 52: 712–719.
95.
MabjeeshN.J., ChenJ., StengerA., MatzkinH.Preimplant predictive factors of urinary retention after iodine 125 prostate brachytherapy. Urology2007; 70: 548–553.
96.
HunterG.K., ReddyC.A., KleinE.A.Long-term (10-year) gastrointestinal and genitourinary toxicity after treatment with external beam radiotherapy, radical prostatectomy, or brachytherapy for prostate cancer. Prostate Cancer2012; 2012: 853487.
97.
HsuI.C., KyounghwaB., ShinoharaK.Trial of combined high-dose-rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: preliminary results of RTOG 0321. Int J Radiat Oncol Biol Phys2010; 78: 751–758.
98.
SnyderK.M., StockR.G., BucksteinM., StoneN.N.Long-term potency preservation following brachytherapy for prostate cancer. BJU Int2012; 110: 221–225.
99.
GibertiC., ChionoL., GalloF., SchenoneM., GastaldiE.Radical retropubic prostatectomy versus brachytherapy for low-risk prostatic cancer: a prospective study. World J Urol2009; 27: 607–612.
100.
CrookJ.M., Gomez-IturriagaA., WallaceK.Comparison of health related quality of life 5 years after SPIRIT: Surgical Prostatectomy Versus Interstitial Radiation Intervention Trial. J Clin Oncol2011; 29(4): 362–368.
101.
HayesJ.H., OllendorfD.A., PearsonS.D.Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA2010; 304: 2373–2380.
102.
PunnenS., CooperbergM.R., D'AmicoA.V.Management of Biochemical Recurrence After Primary Treatment of Prostate Cancer: A Systematic Review of the Literature. Eur Urol2013. [Epub ahead of print].
103.
LosaA., NavaL.D., Di MuzioN.Salvage brachytherapy for local recurrence after radical prostatectomy and subsequent external beam radiotherapy. Urology2003; 62: 1068–1072.
104.
NiehoffP., LochT., NürnbergN.Feasibility and preliminary outcome of salvage combined HDR brachytherapyand external beam radiotherapy (EBRT) for local recurrences after radical prostatectomy. Brachytherapy2005; 4: 141–145.
105.
TraudtK., CiezkiJ., KleinE.A.Prostatecancer recurrence after radicalprostatectomy. Urology2011; 77: 1416–1419.
